Details
Stereochemistry | ACHIRAL |
Molecular Formula | C20H21ClO4 |
Molecular Weight | 360.832 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)OC(=O)C(C)(C)Oc1ccc(cc1)C(=O)c2ccc(cc2)Cl
InChI
InChIKey=YMTINGFKWWXKFG-UHFFFAOYSA-N
InChI=1S/C20H21ClO4/c1-13(2)24-19(23)20(3,4)25-17-11-7-15(8-12-17)18(22)14-5-9-16(21)10-6-14/h5-13H,1-4H3
Molecular Formula | C20H21ClO4 |
Molecular Weight | 360.832 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionCurator's Comment:: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/25903954
Curator's Comment:: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/25903954
Fenofibrate is a drug of the fibrate class. It is mainly used to reduce cholesterol levels in people at risk of cardiovascular disease. It’s used as adjunctive therapy to diet to reduce elevated LDL-C, Total-C,Triglycerides and Apo B, and to increase HDL-C in adult patients with primary hypercholesterolemia or mixed dyslipidemia (Fredrickson Types IIa and IIb). Fenofibrate is a fibric acid derivative, a prodrug comprising fenofibric acid linked to an isopropyl ester. Fenofibrate is rapidly hydrolyzed after oral ingestion to its pharmacologically active form, fenofibric acid. The effects of fenofibric acid seen in clinical practice have been explained in vivo in transgenic mice and in vitro in human hepatocyte cultures by the activation of peroxisome proliferator activated receptor α (PPARα). It lowers lipid levels by activating peroxisome proliferator-activated receptor alpha (PPARα). PPARα activates lipoprotein lipase and reduces apoprotein CIII (an inhibitor of lipoprotein lipase activity), which increases lipolysis and elimination of triglyceride-rich particles from plasma. The resulting fall in triglycerides produces an alteration in the size and composition of LDL from small, dense particles (which are thought to be atherogenic due to their susceptibility to oxidation), to large buoyant particles. These larger particles have a greater affinity for cholesterol receptors and are catabolized rapidly. PPARα also increases apoproteins AI and AII, reduces VLDL- and LDL-containing apoprotein B, and increases HDL-containing apoprotein AI and AII.Fenofibrate also reduces serum uric acid levels in hyperuricemic and normal individuals by increasing the urinary excretion of uric acid. Fenofibrate also has an off-label use as uricosuric therapy in people who have gout.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/25903954
Curator's Comment:: fenofbrate cannot cross the blood-brain barrier and reach the central nervous system
Originator
Curator's Comment:: Procetofen was synthesized in 1974 and was introduced in clinical practice in France the same year. Procetofen, which significantly decreased plasma lipid concentrations in hyperlipidemic patients, was later called fenofibrate to comply with World Health Organization nomenclature guidelines
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL239 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26693220 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | TRICOR Approved UseTreatment of Hypercholesterolemia. TRICOR is indicated as adjunctive therapy to diet to reduce elevated LDL-C, Total-C, Triglycerides
and Apo B, and to increase HDL-C in adult patients with primary hypercholesterolemia or mixed dyslipidemia (Fredrickson Types IIa and IIb). lipid-altering agents should be used in addition to a diet restricted in saturated fat and cholesterol when response to diet and non-pharmacological interventions alone has been inadequate (see National Cholesterol Education Program [NCEP] Treatment
Treatment of Hypertriglyceridemia: TRICOR is also indicated as adjunctive therapy to diet for treatment of adult patients with
hypertriglyceridemia (Fredrickson Types IV and V hyperlipidemia). Improving glycemic control in diabetic patients showing fasting chylomicronemia will usually reduce fasting triglycerides and eliminate chylomicronemia thereby obviating the need for pharmacologic intervention. Launch Date1.09952644E12 |
|||
Palliative | TRICOR Approved UseTreatment of Hypercholesterolemia. TRICOR is indicated as adjunctive therapy to diet to reduce elevated LDL-C, Total-C, Triglycerides
and Apo B, and to increase HDL-C in adult patients with primary hypercholesterolemia or mixed dyslipidemia (Fredrickson Types IIa and IIb). lipid-altering agents should be used in addition to a diet restricted in saturated fat and cholesterol when response to diet and non-pharmacological interventions alone has been inadequate (see National Cholesterol Education Program [NCEP] Treatment
Treatment of Hypertriglyceridemia: TRICOR is also indicated as adjunctive therapy to diet for treatment of adult patients with
hypertriglyceridemia (Fredrickson Types IV and V hyperlipidemia). Improving glycemic control in diabetic patients showing fasting chylomicronemia will usually reduce fasting triglycerides and eliminate chylomicronemia thereby obviating the need for pharmacologic intervention. Launch Date1.09952644E12 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1.96 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27648957 |
67 mg single, oral dose: 67 mg route of administration: Oral experiment type: SINGLE co-administered: |
FENOFIBRIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
51.9 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27648957 |
67 mg single, oral dose: 67 mg route of administration: Oral experiment type: SINGLE co-administered: |
FENOFIBRIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
22.1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27648957 |
67 mg single, oral dose: 67 mg route of administration: Oral experiment type: SINGLE co-administered: |
FENOFIBRIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
16 h |
160 mg 1 times / day multiple, oral dose: 160 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
FENOFIBRIC ACID serum | Homo sapiens population: HEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1% |
160 mg 1 times / day multiple, oral dose: 160 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
FENOFIBRIC ACID serum | Homo sapiens population: HEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
200 mg 1 times / day multiple, oral Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: |
unhealthy, 49.5 n = 87 Health Status: unhealthy Condition: dyslipidemia Age Group: 49.5 Sex: M+F Population Size: 87 Sources: |
Other AEs: Asthenia, Pain... Other AEs: Asthenia (1.1%) Sources: Pain (1.1%) Headache (3.4%) Migraine (2.3%) Dyspepsia (2.3%) Gastrointestinal disorder (1.1%) Nausea (3.4%) Diarrhoea (1.1%) Myalgia (1.1%) Dizziness (1.1%) Abnormal thinking (1.1%) |
145 mg 1 times / day multiple, oral Recommended Dose: 145 mg, 1 times / day Route: oral Route: multiple Dose: 145 mg, 1 times / day Sources: |
unhealthy, adult n = 439 Health Status: unhealthy Condition: dyslipidemia Age Group: adult Population Size: 439 Sources: |
Other AEs: Abdominal pain, Back pain... Other AEs: Abdominal pain (4.6%) Sources: Back pain (3.4%) Headache (3.2%) Nausea (2.3%) Constipation (2.1%) Abnormal liver function tests (7.5%) ALT increased (3%) CPK increased (3%) AST increased (3.4%) Respiratory disorder (6.2%) Rhinitis (2.3%) Urticaria (1.1%) Rash (1.4%) |
200 mg 2 times / day multiple, oral Highest studied dose Dose: 200 mg, 2 times / day Route: oral Route: multiple Dose: 200 mg, 2 times / day Sources: |
unhealthy n = 46 Health Status: unhealthy Condition: hyperlipoproteinaemia Sex: M+F Population Size: 46 Sources: |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Abnormal thinking | 1.1% | 200 mg 1 times / day multiple, oral Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: |
unhealthy, 49.5 n = 87 Health Status: unhealthy Condition: dyslipidemia Age Group: 49.5 Sex: M+F Population Size: 87 Sources: |
Asthenia | 1.1% | 200 mg 1 times / day multiple, oral Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: |
unhealthy, 49.5 n = 87 Health Status: unhealthy Condition: dyslipidemia Age Group: 49.5 Sex: M+F Population Size: 87 Sources: |
Diarrhoea | 1.1% | 200 mg 1 times / day multiple, oral Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: |
unhealthy, 49.5 n = 87 Health Status: unhealthy Condition: dyslipidemia Age Group: 49.5 Sex: M+F Population Size: 87 Sources: |
Dizziness | 1.1% | 200 mg 1 times / day multiple, oral Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: |
unhealthy, 49.5 n = 87 Health Status: unhealthy Condition: dyslipidemia Age Group: 49.5 Sex: M+F Population Size: 87 Sources: |
Gastrointestinal disorder | 1.1% | 200 mg 1 times / day multiple, oral Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: |
unhealthy, 49.5 n = 87 Health Status: unhealthy Condition: dyslipidemia Age Group: 49.5 Sex: M+F Population Size: 87 Sources: |
Myalgia | 1.1% | 200 mg 1 times / day multiple, oral Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: |
unhealthy, 49.5 n = 87 Health Status: unhealthy Condition: dyslipidemia Age Group: 49.5 Sex: M+F Population Size: 87 Sources: |
Pain | 1.1% | 200 mg 1 times / day multiple, oral Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: |
unhealthy, 49.5 n = 87 Health Status: unhealthy Condition: dyslipidemia Age Group: 49.5 Sex: M+F Population Size: 87 Sources: |
Dyspepsia | 2.3% | 200 mg 1 times / day multiple, oral Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: |
unhealthy, 49.5 n = 87 Health Status: unhealthy Condition: dyslipidemia Age Group: 49.5 Sex: M+F Population Size: 87 Sources: |
Migraine | 2.3% | 200 mg 1 times / day multiple, oral Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: |
unhealthy, 49.5 n = 87 Health Status: unhealthy Condition: dyslipidemia Age Group: 49.5 Sex: M+F Population Size: 87 Sources: |
Headache | 3.4% | 200 mg 1 times / day multiple, oral Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: |
unhealthy, 49.5 n = 87 Health Status: unhealthy Condition: dyslipidemia Age Group: 49.5 Sex: M+F Population Size: 87 Sources: |
Nausea | 3.4% | 200 mg 1 times / day multiple, oral Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: |
unhealthy, 49.5 n = 87 Health Status: unhealthy Condition: dyslipidemia Age Group: 49.5 Sex: M+F Population Size: 87 Sources: |
Urticaria | 1.1% | 145 mg 1 times / day multiple, oral Recommended Dose: 145 mg, 1 times / day Route: oral Route: multiple Dose: 145 mg, 1 times / day Sources: |
unhealthy, adult n = 439 Health Status: unhealthy Condition: dyslipidemia Age Group: adult Population Size: 439 Sources: |
Rash | 1.4% | 145 mg 1 times / day multiple, oral Recommended Dose: 145 mg, 1 times / day Route: oral Route: multiple Dose: 145 mg, 1 times / day Sources: |
unhealthy, adult n = 439 Health Status: unhealthy Condition: dyslipidemia Age Group: adult Population Size: 439 Sources: |
Constipation | 2.1% | 145 mg 1 times / day multiple, oral Recommended Dose: 145 mg, 1 times / day Route: oral Route: multiple Dose: 145 mg, 1 times / day Sources: |
unhealthy, adult n = 439 Health Status: unhealthy Condition: dyslipidemia Age Group: adult Population Size: 439 Sources: |
Nausea | 2.3% | 145 mg 1 times / day multiple, oral Recommended Dose: 145 mg, 1 times / day Route: oral Route: multiple Dose: 145 mg, 1 times / day Sources: |
unhealthy, adult n = 439 Health Status: unhealthy Condition: dyslipidemia Age Group: adult Population Size: 439 Sources: |
Rhinitis | 2.3% | 145 mg 1 times / day multiple, oral Recommended Dose: 145 mg, 1 times / day Route: oral Route: multiple Dose: 145 mg, 1 times / day Sources: |
unhealthy, adult n = 439 Health Status: unhealthy Condition: dyslipidemia Age Group: adult Population Size: 439 Sources: |
ALT increased | 3% | 145 mg 1 times / day multiple, oral Recommended Dose: 145 mg, 1 times / day Route: oral Route: multiple Dose: 145 mg, 1 times / day Sources: |
unhealthy, adult n = 439 Health Status: unhealthy Condition: dyslipidemia Age Group: adult Population Size: 439 Sources: |
CPK increased | 3% | 145 mg 1 times / day multiple, oral Recommended Dose: 145 mg, 1 times / day Route: oral Route: multiple Dose: 145 mg, 1 times / day Sources: |
unhealthy, adult n = 439 Health Status: unhealthy Condition: dyslipidemia Age Group: adult Population Size: 439 Sources: |
Headache | 3.2% | 145 mg 1 times / day multiple, oral Recommended Dose: 145 mg, 1 times / day Route: oral Route: multiple Dose: 145 mg, 1 times / day Sources: |
unhealthy, adult n = 439 Health Status: unhealthy Condition: dyslipidemia Age Group: adult Population Size: 439 Sources: |
AST increased | 3.4% | 145 mg 1 times / day multiple, oral Recommended Dose: 145 mg, 1 times / day Route: oral Route: multiple Dose: 145 mg, 1 times / day Sources: |
unhealthy, adult n = 439 Health Status: unhealthy Condition: dyslipidemia Age Group: adult Population Size: 439 Sources: |
Back pain | 3.4% | 145 mg 1 times / day multiple, oral Recommended Dose: 145 mg, 1 times / day Route: oral Route: multiple Dose: 145 mg, 1 times / day Sources: |
unhealthy, adult n = 439 Health Status: unhealthy Condition: dyslipidemia Age Group: adult Population Size: 439 Sources: |
Abdominal pain | 4.6% | 145 mg 1 times / day multiple, oral Recommended Dose: 145 mg, 1 times / day Route: oral Route: multiple Dose: 145 mg, 1 times / day Sources: |
unhealthy, adult n = 439 Health Status: unhealthy Condition: dyslipidemia Age Group: adult Population Size: 439 Sources: |
Respiratory disorder | 6.2% | 145 mg 1 times / day multiple, oral Recommended Dose: 145 mg, 1 times / day Route: oral Route: multiple Dose: 145 mg, 1 times / day Sources: |
unhealthy, adult n = 439 Health Status: unhealthy Condition: dyslipidemia Age Group: adult Population Size: 439 Sources: |
Abnormal liver function tests | 7.5% | 145 mg 1 times / day multiple, oral Recommended Dose: 145 mg, 1 times / day Route: oral Route: multiple Dose: 145 mg, 1 times / day Sources: |
unhealthy, adult n = 439 Health Status: unhealthy Condition: dyslipidemia Age Group: adult Population Size: 439 Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: 3.0 |
moderate | |||
Page: 3.0 |
no | |||
Page: 3.0 |
no | |||
Page: 3.0 |
no | |||
Page: 3.0 |
no | |||
Page: 3.0 |
weak | |||
Page: 3.0 |
weak | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/26700956/ Page: 16.0 |
yes [IC50 170 uM] | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/15601807/ Page: 6.0 |
yes [IC50 2.39 uM] | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/14698041/ Page: 4.0 |
yes [IC50 5.83 uM] | |||
yes [Inhibition 50 uM] | ||||
yes [Ki 105.2 uM] | ||||
Sources: https://pubmed.ncbi.nlm.nih.gov/14685799/ |
yes |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://pubmed.ncbi.nlm.nih.gov/14698041/ Page: 1.0 |
no | |||
yes | ||||
yes | ||||
yes | ||||
yes | ||||
Sources: https://pubmed.ncbi.nlm.nih.gov/15304429/ Page: 3.0 |
yes |
PubMed
Title | Date | PubMed |
---|---|---|
Statins enhance arachidonic acid synthesis in hypercholesterolemic patients. | 2001 Apr |
|
LpAI in HDL subfractions: serum levels in men and women with coronary heart disease and changes under hypolipemic therapy. | 2001 Apr |
|
Fenofibrate raises plasma homocysteine levels in the fasted and fed states. | 2001 Apr |
|
Serum uric acid levels: a useful but not absolute marker of compliance with fenofibrate treatment. | 2001 Dec |
|
Rare side-effects of fenofibrate. | 2001 Feb |
|
Comparative effects of cerivastatin and fenofibrate on the atherogenic lipoprotein phenotype in proteinuric renal disease. | 2001 Feb |
|
Homocysteine and lipid lowering agents. A comparison between atorvastatin and fenofibrate in patients with mixed hyperlipidemia. | 2001 Feb 1 |
|
Rapid and simple method for detection of fenofibric acid in human serum by high-performance liquid chromatography. | 2001 Jan |
|
Effects of atorvastatin versus fenofibrate on lipoprotein profiles, low-density lipoprotein subfraction distribution, and hemorheologic parameters in type 2 diabetes mellitus with mixed hyperlipoproteinemia. | 2001 Jan 1 |
|
Abundant expression of uncoupling protein-2 in the small intestine: up-regulation by dietary fish oil and fibrates. | 2001 Jan 15 |
|
PPARalpha agonists inhibit tissue factor expression in human monocytes and macrophages. | 2001 Jan 16 |
|
Effect of fenofibrate on fatty liver in rats treated with alcohol. | 2001 Jun |
|
Preferential reduction of very low density lipoprotein-1 particle number by fenofibrate in type IIB hyperlipidemia: consequences for lipid accumulation in human monocyte-derived macrophages. | 2001 Mar |
|
Plasma vascular endothelial growth factor and its receptor Flt-1 in patients with hyperlipidemia and atherosclerosis and the effects of fluvastatin or fenofibrate. | 2001 May 15 |
|
Fibrates and homocysteine. | 2001 Nov-Dec |
|
[Photoaggravated contact allergy and contact photoallergy caused by ketoprofen: 19 cases]. | 2001 Oct |
|
Effect of fenofibrate on plasma concentration and urinary excretion of purine bases and oxypurinol. | 2001 Oct |
|
[Pleiotrophic effect of anti-hyperlipemic agents]. | 2001 Oct 10 |
|
Functional analysis of the transcriptional activity of the mouse phospholipid transfer protein gene. | 2001 Oct 5 |
|
Cerivastatin and gemfibrozil-associated rhabdomyolysis. | 2001 Sep |
|
Impact of postprandial hypertriglyceridemia on vascular responses in patients with coronary artery disease: effects of ACE inhibitors and fibrates. | 2001 Sep |
|
[Studies on the risk factors for fenofibrate-induced elevation of liver function tests]. | 2002 Feb |
|
Prediction of poly(ethylene) glycol-drug eutectic compositions using an index based on the van't Hoff equation. | 2002 Mar |
|
Fenofibrate lowers plasma triglycerides and increases LDL particle diameter in subjects with type 2 diabetes. | 2002 Mar |
Sample Use Guides
Primary Hypercholesterolemia or Mixed Hyperlipidemia: the initial dose of TRICOR (FENOFIBRATE TABLETS) is 145 mg per day
Hypertriglyceridemia: the initial dose is 48 to 145 mg per day
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/27629528
Fenofibrate may protect against endothelin-1 (ET-1)-induced cardiomyocyte hypertrophy and enhanced adiponectin expression through modulation of PPARα expression in vitro and limitation of daunorubicin cardiotoxicity in vivo, suggesting a novel mechanistic insight into the role of PPARα and adiponectin in cardiachypertrophy and heart failure.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Jun 25 20:59:45 UTC 2021
by
admin
on
Fri Jun 25 20:59:45 UTC 2021
|
Record UNII |
U202363UOS
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NDF-RT |
N0000175375
Created by
admin on Fri Jun 25 20:59:45 UTC 2021 , Edited by admin on Fri Jun 25 20:59:45 UTC 2021
|
||
|
WHO-VATC |
QC10BA03
Created by
admin on Fri Jun 25 20:59:45 UTC 2021 , Edited by admin on Fri Jun 25 20:59:45 UTC 2021
|
||
|
WHO-ATC |
C10BA04
Created by
admin on Fri Jun 25 20:59:45 UTC 2021 , Edited by admin on Fri Jun 25 20:59:45 UTC 2021
|
||
|
LIVERTOX |
403
Created by
admin on Fri Jun 25 20:59:45 UTC 2021 , Edited by admin on Fri Jun 25 20:59:45 UTC 2021
|
||
|
NCI_THESAURUS |
C98150
Created by
admin on Fri Jun 25 20:59:45 UTC 2021 , Edited by admin on Fri Jun 25 20:59:45 UTC 2021
|
||
|
WHO-VATC |
QC10AB05
Created by
admin on Fri Jun 25 20:59:45 UTC 2021 , Edited by admin on Fri Jun 25 20:59:45 UTC 2021
|
||
|
WHO-ATC |
C10BA03
Created by
admin on Fri Jun 25 20:59:45 UTC 2021 , Edited by admin on Fri Jun 25 20:59:45 UTC 2021
|
||
|
WHO-ATC |
C10AB05
Created by
admin on Fri Jun 25 20:59:45 UTC 2021 , Edited by admin on Fri Jun 25 20:59:45 UTC 2021
|
||
|
WHO-VATC |
QC10BA04
Created by
admin on Fri Jun 25 20:59:45 UTC 2021 , Edited by admin on Fri Jun 25 20:59:45 UTC 2021
|
||
|
NDF-RT |
N0000170118
Created by
admin on Fri Jun 25 20:59:45 UTC 2021 , Edited by admin on Fri Jun 25 20:59:45 UTC 2021
|
||
|
NDF-RT |
N0000175596
Created by
admin on Fri Jun 25 20:59:45 UTC 2021 , Edited by admin on Fri Jun 25 20:59:45 UTC 2021
|
||
|
NDF-RT |
N0000170118
Created by
admin on Fri Jun 25 20:59:45 UTC 2021 , Edited by admin on Fri Jun 25 20:59:45 UTC 2021
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
3996
Created by
admin on Fri Jun 25 20:59:45 UTC 2021 , Edited by admin on Fri Jun 25 20:59:45 UTC 2021
|
PRIMARY | |||
|
SUB07576MIG
Created by
admin on Fri Jun 25 20:59:45 UTC 2021 , Edited by admin on Fri Jun 25 20:59:45 UTC 2021
|
PRIMARY | |||
|
7186
Created by
admin on Fri Jun 25 20:59:45 UTC 2021 , Edited by admin on Fri Jun 25 20:59:45 UTC 2021
|
PRIMARY | |||
|
7736
Created by
admin on Fri Jun 25 20:59:45 UTC 2021 , Edited by admin on Fri Jun 25 20:59:45 UTC 2021
|
PRIMARY | |||
|
C29047
Created by
admin on Fri Jun 25 20:59:45 UTC 2021 , Edited by admin on Fri Jun 25 20:59:45 UTC 2021
|
PRIMARY | |||
|
49562-28-9
Created by
admin on Fri Jun 25 20:59:45 UTC 2021 , Edited by admin on Fri Jun 25 20:59:45 UTC 2021
|
PRIMARY | |||
|
CHEMBL672
Created by
admin on Fri Jun 25 20:59:45 UTC 2021 , Edited by admin on Fri Jun 25 20:59:45 UTC 2021
|
PRIMARY | |||
|
221100
Created by
admin on Fri Jun 25 20:59:45 UTC 2021 , Edited by admin on Fri Jun 25 20:59:45 UTC 2021
|
PRIMARY | |||
|
DB01039
Created by
admin on Fri Jun 25 20:59:45 UTC 2021 , Edited by admin on Fri Jun 25 20:59:45 UTC 2021
|
PRIMARY | |||
|
U202363UOS
Created by
admin on Fri Jun 25 20:59:45 UTC 2021 , Edited by admin on Fri Jun 25 20:59:45 UTC 2021
|
PRIMARY | |||
|
256-376-3
Created by
admin on Fri Jun 25 20:59:45 UTC 2021 , Edited by admin on Fri Jun 25 20:59:45 UTC 2021
|
PRIMARY | |||
|
Fenofibrate
Created by
admin on Fri Jun 25 20:59:45 UTC 2021 , Edited by admin on Fri Jun 25 20:59:45 UTC 2021
|
PRIMARY | |||
|
D011345
Created by
admin on Fri Jun 25 20:59:45 UTC 2021 , Edited by admin on Fri Jun 25 20:59:45 UTC 2021
|
PRIMARY | |||
|
1152
Created by
admin on Fri Jun 25 20:59:45 UTC 2021 , Edited by admin on Fri Jun 25 20:59:45 UTC 2021
|
PRIMARY | |||
|
8703
Created by
admin on Fri Jun 25 20:59:45 UTC 2021 , Edited by admin on Fri Jun 25 20:59:45 UTC 2021
|
ALTERNATIVE | |||
|
FENOFIBRATE
Created by
admin on Fri Jun 25 20:59:45 UTC 2021 , Edited by admin on Fri Jun 25 20:59:45 UTC 2021
|
PRIMARY | |||
|
M5279
Created by
admin on Fri Jun 25 20:59:45 UTC 2021 , Edited by admin on Fri Jun 25 20:59:45 UTC 2021
|
PRIMARY | Merck Index | ||
|
49562-28-9
Created by
admin on Fri Jun 25 20:59:45 UTC 2021 , Edited by admin on Fri Jun 25 20:59:45 UTC 2021
|
PRIMARY | |||
|
3339
Created by
admin on Fri Jun 25 20:59:45 UTC 2021 , Edited by admin on Fri Jun 25 20:59:45 UTC 2021
|
PRIMARY | |||
|
1269447
Created by
admin on Fri Jun 25 20:59:45 UTC 2021 , Edited by admin on Fri Jun 25 20:59:45 UTC 2021
|
PRIMARY | USP-RS |
Related Record | Type | Details | ||
---|---|---|---|---|
|
BINDER->LIGAND |
BINDING
|
||
|
TRANSPORTER -> INHIBITOR |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE ACTIVE -> PRODRUG |
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Biological Half-life | PHARMACOKINETIC |
|
|
|||